GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Shiller PE Ratio

Capricor Therapeutics (FRA:4LN2) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Capricor Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Capricor Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Shiller PE Ratio Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Capricor Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Capricor Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Capricor Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Shiller PE Ratio falls into.



Capricor Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Capricor Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Capricor Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.285/131.7762*131.7762
=-0.285

Current CPI (Mar. 2024) = 131.7762.

Capricor Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.957 100.560 -1.254
201409 -1.009 100.428 -1.324
201412 -1.298 99.070 -1.727
201503 -2.125 99.621 -2.811
201506 -1.693 100.684 -2.216
201509 -1.604 100.392 -2.105
201512 -1.928 99.792 -2.546
201603 -2.335 100.470 -3.063
201606 -2.314 101.688 -2.999
201609 -2.584 101.861 -3.343
201612 -1.991 101.863 -2.576
201703 -1.589 102.862 -2.036
201706 -1.424 103.349 -1.816
201709 -1.007 104.136 -1.274
201712 3.549 104.011 4.496
201803 -1.135 105.290 -1.421
201806 -1.216 106.317 -1.507
201809 -1.157 106.507 -1.432
201812 -0.967 105.998 -1.202
201903 -0.664 107.251 -0.816
201906 -0.522 108.070 -0.637
201909 -0.390 108.329 -0.474
201912 -0.306 108.420 -0.372
202003 -0.271 108.902 -0.328
202006 -0.204 108.767 -0.247
202009 -0.170 109.815 -0.204
202012 -0.173 109.897 -0.207
202103 -0.193 111.754 -0.228
202106 -0.174 114.631 -0.200
202109 -0.145 115.734 -0.165
202112 -0.230 117.630 -0.258
202203 -0.291 121.301 -0.316
202206 -0.274 125.017 -0.289
202209 -0.263 125.227 -0.277
202212 -0.293 125.222 -0.308
202303 -0.290 127.348 -0.300
202306 -0.268 128.729 -0.274
202309 -0.234 129.860 -0.237
202312 0.018 129.419 0.018
202403 -0.285 131.776 -0.285

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Capricor Therapeutics  (FRA:4LN2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Capricor Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics (FRA:4LN2) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines